Endologix (Irvine, California), a company that recently merged with TriVascular (Santa Rosa, California), announced that its Ovation Alto Abdominal Stent Graft System has been implanted in two patients for the first time.
Still an investigational device and not approved for sale in any market, the Ovation Alto is designed to allow more patients to benefit from endovascular aortic repair (EVAR) that have short and difficult to work with aortic necks. This is thanks to shape changing O-rings that have been positioned at the end of the device, sealing the lumen just below the renal arteries.
The implantations took place at the Auckland City Hospital in New Zealand and the company believes it can obtain regulatory approval in Europe next year and in the U.S. in 2018.
Dr. Andrew Hill, one of the surgeons who worked on implanting the Ovation Alto had the following to say in a press release: “The Ovation Alto system has the potential to increase the number of AAA patients treated with EVAR due to its unique sealing technology and ultra-low profile design. The new system is designed to provide the broadest indications of all infrarenal EVAR devices, which represents an important advancement for physicians and their AAA patients.”